Studie

An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib

Erkrankungsgruppe:

Sonstiges

Organsystem:

Sonstiges

Stadium:

Therapierefraktär

Standort:

Universitätsklinikum Köln

EudraCT:

2015-001922-40

Prüfplan-Code:

CLDK378A2X01B

Phase:

IV

Prüfsubstanz:

LDK378, Ceritinib

Sponsor:

Novartis